Canada To Trial Step-Wise Review Of Biosimilars
This article was originally published in SRA
Executive Summary
Health Canada has launched a three-year pilot to explore a step-wise review approach under which companies developing biosimilar medicines will be able to request a scientific advice meeting on their comparability package at an earlier stage to help ensure that the review proceeds as smoothly as possible1.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.